Oncology ResearchExpansive 393-target assay reveals gene fusions and key resistance mutations in 75 cancer-related genes, including those ob-served in Ph-like ALL, with MET and EPOR splicing

For Research Use Only. Not for use in diagnostic procedures. APM012 Rev. A

ABL1 ABL1ABL2 ABL2AKT1 AKT1 AKT1AKT2 AKT2AKT3 AKT3 AKT3ALK ALK ALK ALK ALK ALKARHGAP26 ARHGAP26 ARHGAP26AXL AXL AXL AXLBRAF BRAF BRAF BRAFBRD3 BRD3 BRD3BRD4 BRD4 BRD4CALCA CALCACAMTA1 CAMTA1CCNB3 CCNB3CCND1 CCND1CIC CICCRLF2 CRLF2CSF1R CSF1RCTNNB1 CTNNB1DDR2 DDR2EGFR EGFR EGFR EGFREPC1 EPC1EPOR EPORERBB2 ERBB2 ERBB2ERBB4 ERBB4ERG ERG ERGESR1 ESR1 ESR1ESRRA ESRRA ESRRAETV1 ETV1 ETV1ETV4 ETV4 ETV4ETV5 ETV5 ETV5ETV6 ETV6 ETV6EWSR1 EWSR1 EWSR1 EWSR1FGFR1 FGFR1 FGFR1 FGFR1FGFR2 FGFR2 FGFR2 FGFR2FGFR3 FGFR3 FGFR3 FGFR3FGR FGR FGRFOXO1 FOXO1FUS FUSGLI1 GLI1GNAS GNASHMGA2 HMGA2HRAS HRASIDH1 IDH1IDH2 IDH2IL2RB IL2RBINSR INSR INSRJAK1 JAK1JAK2 JAK2JAK3 JAK3JAZF1 JAZF1

FusionPlexALK, RET,ROS1 v2

FusionPlex Sarcoma

FusionPlex Oncology Research

FusionPlex CTL

FusionPlex Solid Tumor

1M1.5M 3M1.5M 3M

Comprehensive target list

Sequencing reads required:

ALK RET ROS1 v2Essential 29-target assay detects gene-fusions and key resistance mutations in ALK, RET, and ROS1

CTL - Thyroid/LungFocused 195-target assay identifies gene-fusions and SNVs implicated in thy-roid and lung cancers, including MET and EGFR splicing

Solid Tumor Comprehensive 288-target assay uncov-ers gene-fusions in 53 genes associated with various carcinomas, including MET and EGFR splicing

For Research Use Only. Not for use in diagnostic procedures. APM012 Rev. A

KIT KITKRAS KRASKRT20 KRT20KRT7 KRT7MAML2 MAML2 MAML2MAP2K1 MAP2K1MAST1 MAST1 MAST1MAST2 MAST2 MAST2MEAF6 MEAF6MET MET MET METMKL2 MKL2MSMB MSMB MSMBMUSK MUSK MUSKMYB MYB MYBMYC MYCNCOA2 NCOA2NOTCH1 NOTCH1 NOTCH1NOTCH2 NOTCH2 NOTCH2NRAS NRASNRG1 NRG1 NRG1 NRG1NTRK1 NTRK1 NTRK1 NTRK1NTRK2 NTRK2 NTRK2 NTRK2NTRK3 NTRK3 NTRK3 NTRK3 NTRK3NUMBL NUMBL NUMBLNUTM1 NUTM1 NUTM1PDGFB PDGFBPDGFRA PDGFRA PDGFRAPDGFRB PDGFRB PDGFRBPIK3CA PIK3CA PIK3CA PIK3CAPKN1 PKN1 PKN1PLAG1 PLAG1PPARG PPARG PPARG PPARGPRKCA PRKCA PRKCAPRKCB PRKCB PRKCBPTH PTHPTK2B PTK2BRAF1 RAF1 RAF1 RAF1RARA RARARELA RELA RELARET RET RET RET RETROS1 ROS1 ROS1 ROS1 ROS1 ROS1RSPO2 RSPO2 RSPO2RSPO3 RSPO3 RSPO3SLC5A5 SLC5A5SS18 SS18STAT6 STAT6SYK SYKTAF15 TAF15TCF12 TCF12TERT TERT TERTTFE3 TFE3 TFE3 TFE3TFEB TFEB TFEBTFG TFGTHADA THADA THADA THADATMPRSS2 TMPRSS2 TMPRSS2TSLP TSLPTTF1 TTF1TYK2 TYK2USP6 USP6YWHAE YWHAE

SarcomaConsolidated 148-target assay exposes known and novel fusions in 26 genes commonly associated with soft tissue cancers

The Archer SureShot ALK, RET, ROS1 Positive Controls consist of 4 FFPE curls containing cell lines with physiologically relevant abundance of ALK, RET and ROS1 fusions, specifically:

• EML4-ALK variant 1• ROS1-SL34A2• RET-CCDC6

Each curl contains a defined mixture of 3 different ALK, RET, and ROS1 fusion-positive cell lines along with a wild-type parental strain.

SureShot Positive and Negative controls are suitable for use with all FusionPlex panels containing these genes.

Learn more at archerdx.com/fusionplex